US03237H1014
US03237H1014
Amylyx Pharmaceuticals, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | -- | 87.371.000 | -- |
| Cost of Revenue | -- | 124.633.000 | -- |
| Gross Profit | -- | -37.262.000 | -- |
| 153.291.000 | 218.415.000 | 29.8% | |
| Operating Income | -153.291.000 | -255.677.000 | 40.0% |
| Pretax Income | -144.689.000 | -302.136.000 | 52.1% |
| Net Income Common Stockholders | -144.735.000 | -301.743.000 | 52.0% |
| -- | -- | -- | |
| -- | -- | -- |